The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Investigating drivers of non-relapse mortality following CAR-T therapy in hematological malignancies
Kai Rejeski, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, shares the findings of a meta-analysis which investigated drivers of non-relapse mortality (NRM) following CAR-T therapy using data from clinical trials and real-world studies (RWS). Data was obtained for all commercially available CAR-T products, and Dr Rejeski summarizes the differences in NRM rates observed across various disease entities. Interestingly, infections were identified as the major driver of NRM, accounting for almost 50% of events. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS/CELGENE
Honoraria: BMS/CELGENE, Novartis
Travel Support: Kite/Gilead, Pierre-Fabre
Research Funding: Kite/Gilead
